The role of Personal KinetiGraph ™ fluctuator score in quantifying the progression of motor fluctuations in Parkinson's disease.

In conclusion, PKG FS can distinguish EF from TF, as well as dyskinetic from non-dyskinetic patients, but cannot discriminate subtler MF. PKG may provide objective MF measures for routine PD management and clinical trials. PMID: 31172936 [PubMed - in process]
Source: Functional Neurology - Category: Neurology Tags: Funct Neurol Source Type: research

Related Links:

This report provides concrete evidence that wheezing is caused by hyperadduction of the false vocal fold as an adverse effect of STN-DBS and can be reversed by adjusting the stimulation site for STN-DBS.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
In this study, we assessed the safety and efficacy of apomorphine sublingual film as an on-demand therapy for off episodes in patients with Parkinson's disease.MethodsThis randomised, double-blind, placebo-controlled study was done by movement disorder specialists at 32 sites in the USA and one in Canada. Patients with Parkinson's disease who had 2 h or more of off time per day with predictable morning off periods, were responsive to levodopa, and were on stable doses of anti-parkinsonian medication were eligible. In an open-label titration phase, increasing doses of apomorphine sublingual film (10–35 mg) were admini...
Source: The Lancet Neurology - Category: Neurology Source Type: research
Although the administration of dopamine precursor levodopa remains as the mainstay for the treatment of Parkinson's disease, long-term exposure to levodopa often causes a disabling complication, referred to as levodopa-induced dyskinesias. Therefore, the development of new therapeutic interventions to dampen levodopa-induced dyskinesias and parkinsonian motor deficits is needed in the treatment of Parkinson's disease. Intracerebral brain infusion has the merit of being able to specifically deliver any drug into any brain part. By using an intracerebral infusion system equipped with implantable, programmable, and refillable...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Conclusion: We confirmed striatal neurovascular dissociation between FDG-PET and perfusion MRI in response to clinically determined anti-parkinsonian medication. We further proposed a novel analytical method to quantify the degree of dissociation in the putamen using only the ON condition scans, Putamen-to-thalamus Hyper-perfusion/hypo-metabolism Index (PHI), which may have the potential to be used as a biomarker for LID (correctly classifying 8 out 10 patients). For wider use of PHI, a larger validation study is warranted.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
What exactly is psychosis? What happens in the brain of a person with schizophrenia who is hallucinating? Schizophrenic Rachel Star Withers shares her personal hallucinations and delusions and Dr. Joseph Goldberg, who specializes in researching what goes on in the brain when someone is experiencing psychosis, joins to break down how the brain functions during psychotic episodes. Host Rachel Star Withers, a diagnosed schizophrenic, and co-host Gabe Howard delve into these intense subjects in this episode of Inside Schizophrenia.  Highlights from “Psychosis in Schizophrenia” Episode [02:13]  Rachel, do...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Brain and Behavior Disorders General Inside Schizophrenia Mental Health and Wellness Active psychosis Delusions Delusions Hallucinations Living with Schizoprenia Mental Disorder Mental Illness Psychology psychotic Psychotic Break Source Type: blogs
CONCLUSION: As it is detected by a survey performed by telephone calls with good interrater reliability, patients with PD gets better with LCIG treatment in many aspects of the disease. PMID: 31731332 [PubMed - as supplied by publisher]
Source: Turkish Journal of Medical Sciences - Category: General Medicine Tags: Turk J Med Sci Source Type: research
This case presented by Agin-Liebes and colleagues demonstrates how the clinical phenotype of a patient with LRRK2-related Parkinson's disease (PD) due to p.G2019S mutation can be indistinguishable from idiopathic PD. To date, at least 3 large studies have compared the clinical features of LRRK2 G2019S PD (N  = 97 to 516 subjects) and idiopathic PD [1–3]. These features included age-of-onset, motor features, cognitive impairment, depression, other non-motor features, levodopa response, and dyskinesia.
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Tags: Correspondence Source Type: research
Abstract Abnormal dopaminergic modulation of the cortico-basal ganglia motor loops results in the emergence of levodopa-induced dyskinesia (LID). We focused on alterations in the gray matter (GM) volume and the cortical thickness of the brain, especially in cortico-basal ganglia motor loops, in Parkinson's disease (PD) with diphasic dyskinesia. 48 PD patients with diphasic dyskinesia, 60 PD patients without dyskinesia and 48 healthy controls (HC) were included. Voxel-based morphometry (VBM) was applied to get GM images from MRI brain images. FreeSurfer was used to get cortical thickness. Distinct analyses of covar...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
This article summarizes our knowledge about a new third-generation COMT inhibitor, namely opicapone (OPC) (Search period: 2016-2019). The authors detail the pharmacological profile of OPC and summarize the results of completed clinical trials. In addition, they briefly summarize the achievements of the past few years.Expert opinion: Based on clinical trials conducted so far, OPC is an effective and safe new drug. In comparison to entacapone and tolcapone, it does not require close laboratory monitoring or multiple oral administrations, which may result in better adherence. No serious adverse event was reported during the d...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Conditions:   Parkinson Disease;   Dyskinesia, Medication-Induced;   L-Dopa Causing Adverse Effects in Therapeutic Use Interventions:   Drug: AV-101;   Drug: Placebo Sponsor:   VistaGen Therapeutics, Inc. Not yet recruiting
Source: - Category: Research Source Type: clinical trials
More News: Brain | Clinical Trials | Dyskinesia | Neurology | Parkinson's Disease | Study